Tisagenlecleucel Versus Blinatumomab or Inotuzumab for Adult Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia: A Randomized Open Label, Multicenter, Phase III Trial
Status: Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Tisagenlecleucel (Primary) ; Blinatumomab; Inotuzumab ozogamicin
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms OBERON
- Sponsors Novartis Pharmaceuticals
- 07 Nov 2019 Planned number of patients changed from 220 to 240.
- 07 Nov 2019 Planned End Date changed from 1 Nov 2023 to 8 Oct 2025.
- 07 Nov 2019 Planned primary completion date changed from 1 Nov 2023 to 8 Oct 2025.